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DISCOVERY OF PYRAZOLOPYRIDINE DERIVATIVES DUALLY TARGETING
INFLAMMATION AND PROLIFERATION IN COLORECTAL CANCER CELL LINES: INSILICO DRUG DESIGN APPROACH
Abstract
Elimination of inflammation represents a promising strategy for cancer prevention and treatment since
cancer and inflammation are related. The combined use of anti-inflammatory agents and cancer therapy
is a focal point. In this frame, pyrazolopyridine derivatives DZ-BAU2021-6 and DZ-BAU2021-14, developed
in BAU Labs, having promising anti-proliferative activity on colon cancer cells HCT-116 and HT-29 with
notable IC50 values and remarkable CDK2 inhibitory effect, were in-silico tested. As an approach to dual
anti-inflammatory anticancer potential, their binding modes and energies on the active site of crystalline
structure of CDK2 and COX2, (1HCK and 3LN1), respectively were explored. Their physicochemical and
pharmacokinetic properties as well as their “drug-likeness” were studied. Computational results declared
that DZ-BAU2021-6 and DZ-BAU2021-14 exhibited high binding affinities to CDK2 and COX2 receptors.
DZ-BAU2021-14 exhibited lower levels of estimated binding energies with COX2 receptor compared to
Celecoxib. It demonstrated high GI absorption, low interference with P-glycoprotein and cytochrome P450
isoforms.
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1. INTRODUCTION
Cancer is a major public health problem and the second leading cause of death worldwide after
cardiovascular diseases. Cancer is a group of malignant neoplasms that can affect any part of the
body; its liability is rising globally with an estimated 18 million new cases and 10 million deaths
every year. Cancer incidence is rapidly rising in all countries, and projected to increase to 30 million
by 2040 (World Health Organization, 2019). There are still too many cancer affected deaths that can
be prevented by early diagnosis and effective treatment (Shamseddine et al., 2014). Colorectal cancer
(CRC) is the fourth world's deadly cancer showing more than 900,000 deaths yearly (Siegel et al.,
2019).
Protein kinases represent a large family of enzymes essential for the regulation of diverse cell
functions through phosphorylation of structural proteins and enzymes regulating cell division. Cyclindependent kinases (CDKs) are members of serine/threonine protein kinase family that have been
implicated as contributing factor in cancer development. Cell cycle progression is mainly controlled
by CDKs, which successively act in G1 to initiate S phase and in G2 to initiate Mitosis (Whittaker et
al., 2017). CDKs phosphorylate cellular substrates required for progression into different cell cycle
phases (Swaffer et al., 2016). Therefore, CDKs are key enzymes in cell cycle control; they are
promising targets for design and discovery of antiproliferative drugs. The majority of CDK inhibitors
are competitive that can bind to ATP pocket and inhibit CDKs activity (Martin MP, 2012). Cyclin
dependent kinase 2 (CDK2), belonging to kinase group, acts as a mediator for cell progression from
G1 to S phases in association with cyclin A and E. In this respect, CDK2 has been actively regarded
as a promising drug target for anticancer therapies (Tarfah Al-Warhi, 2020). Great majority of
clinically used CDK2 inhibitors, although acting by ATP-competition, their structures are quite
diverse and they are generally comprising or derived from various heterocyclic families such as
purines namely Roscovitine and Olomoucine, pyrimidines and indoles as in case of Meridianin, as
well as pyrazoles and thiazoles for Crisotinib and Dasatinib (Bailon-Moscoso et al., 2017; Kim et al.,
2020; Kolodziej et al., 2015; Wu & Fu, 2018). CDk2 expression was proven remarkably upregulated
in colorectum tumorigenesis. Its overexpression promotes the progression of early cancer and
correlates with prognosis in colorectal carcinoma (Li et al., 2001; Yamamoto et al., 1998).
Roscovitine, the potent CDK2 inhibitor, succeeded to treat different cancer types, either as single
therapy or in combination with other agents. It has a noticeable antiproliferative effect on colon cancer
cells HCT-116, HT-29 and other cell lines. Orally administered, Roscovitine caused a reduction in
tumor growth in HCT-116 and HT-29 human colon cancer xenograft model in nude mice of 79% and
80% respectively (Cicenas et al., 2015).
Cancer development is a multi-step process promoted by exposure to chemical irritants or
inflammatory mediators that induce cell proliferation (O'Neill et al., 2018). Cancer and inflammation
are related to each other, where great correlation between formation of precancerous lesions and
inflammation were observed (Matkowskyj et al., 2013). Many reports related overexpression of
different inflammatory mediators in chronic inflammation to cancer risk, increased cell proliferation,
metastasis and angiogenesis. Therefore targeting inflammation could develop good strategy for
cancer therapy and prevention since many epidemiological studies have demonstrated that
inflammation can predispose to tumors (Silvia Zappavigna & Caraglia, 2020). Many reviews traced
cyclooxygenase-2 (COX2), studied the overexpression of its biological products prostaglandin E2
and COX2 mediated factor IL-11 and described their role in regulating angiogenesis, tumorigenesis
and metastasis (Howe, 2007; Singh-Ranger et al., 2008; Singh et al., 2006). In parallel, clinical studies
have indicated that long term use of nonsteroidal anti-inflammatory drugs (NSAIDs) decreased the
incidence of cancer and were believed to play a role in cancer prevention and treatment (Rayburn et
al., 2009; Thun et al., 2002; Wong, 2019).
Sheng et al. described specifically the role of COX2 and related mediators in colorectal
carcinogenesis (Sheng et al., 2020). COX2 signaling and promotion of pathogenesis, angiogenesis
and metastasis of colorectal cancer were comprehensively detailed in near literature (Liu et al., 2017;
Masferrer et al., 2000; Zhou et al., 2017). Numerous epidemiologic studies have found that long-term
users of NSAIDs have a lower risk of colorectal adenomatous polyps and colorectal cancer than
nonusers (Grau et al., 2009; Mayor, 2015; S. Friis, 2015). NSAIDs whether non-selective or selective
COX2 inhibitors were proven curative for some adenomatous colorectal cancer stages where Sulindac
and Celecoxib have been described in a randomized clinical study to reduce the number of polyps
and their size up to 65%. The uses of COX inhibitors for treatment of colorectal cancer have been
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raised since colorectal tumor tissue showed higher concentration of prostaglandin E2 than in
surrounding normal mucosa, randomized clinical trials have confirmed that the prodrug Sulindac and
the selective COX2 inhibitor Celecoxib inhibited the growth of adenomatous polyps in colorectal
cancer (Kemp Bohan et al., 2020; Sheng et al., 2020; Steinbach G & Med, 2000). Combining
Celecoxib and Cetuximab improved the antiproliferative activity by 50% in cetuximab resistant colon
HT-29 cells (Valverde et al., 2017).
Colorectal cancer, that still needs proper and effective treatment, represents a therapeutic target
for drug discovery and development. Co-administration of combined anti-inflammatory anticancer
treatments might be a respectable approach nevertheless their metabolic and excretory burden.
Having acknowledged antiproliferative effect on colon cancer cells HCT-116 and HT-29, the purine
CDK2 inhibitor, Roscovitine was adopted as a lead compound, and directed researchers in the current
work to select isosteric pyrazolopyridine congeners DZ-BAU2021-6 and DZ-BAU2021-14 for
further study. The chosen compounds for investigation are reported to have promising CDK2
inhibitory effect and encouraging antiproliferative activity on colon cancer cells HCT-116 and HT29 (Kassem et al., 2021). DZ-BAU2021-6 and DZ-BAU2021-14 comprise fused pyrazolo core which
is pharmacophoric for COX2 inhibition. The previous stated facts directed the research group to
explore the anti-inflammatory potential of DZ-BAU2021-6 and DZ-BAU2021-14. This might
promote the discovery of individual inhibitors possessing both CDK2 and COX2 activities which
adds highlights towards a twin scope activity saving pharmacokinetic burden of combination
treatment.

2. MATERIAL AND METHODS
2.1. Molecular Docking Studies
In-silico pharmacodynamic studies of DZ-BAU2021-6 and DZ-BAU2021-14 1 were
carried out to gain a perception of their binding forces and energies to the active sites of target
proteins. Mol files of docked compounds were generated by drawing their structures using
ChemSketch (ACD\Labs Chemistry Software) and transformed into PDB format via Open Babel
(O'Boyle et al., 2011). The PDB files of X-ray crystal structures of selected receptors CDK2
(PDB ID: 1HCK) (Schulze-Gahmen et al., 1996) and COX2 (PDB ID: 3ln1) (Wang et al., 2010)
were retrieved from the online protein database (Berman et al., 2000; RCSB-Protein Data Bank).
The crystal structure of target protein 1HCK was treated by removing the co-crystallized ligand
ATP, water and magnesium. Similarly, 3ln1 was freed from Celecoxib and water molecules.
Optimization and energy minimization were achieved using Swiss PDB viewer V.4.1.0 software
(Johansson et al., 2012). AutoDock4.0 software was used to perform Molecular docking based
on Lamarckian Genetic Algorithm (Morris et al., 2009). Polar hydrogens addition to protein and
Kollman united atomic charges were computed using AutoDock hydrogen module. Using Auto
Grid function, grid maps were calculated, Grid size was set to 40*40*40 points and grid spacing
of 0.375 Å. Grid box was assigned to include the active residue in center. Default docking
algorithms were specified in agreement with standard docking protocol. Ten runs were executed
for each ligand using Cygwin (Cygwin project). Lowest binding energies were clustered
according to 1.0 Å RMSD tolerance criteria and estimated inhibition constant Ki and docking
energies were calculated. UCSF Chimera was used for H-bond analysis (Pettersen et al., 2004).
MOE2014.0901 (MOE, 2014) was used to analyze pi bonds, lipophilic, hydrogen donoracceptor interactions and Van der Waals forces of attraction with different amino acids.

2.2. Validation of Molecular Docking
Validation of prepared protein receptor models 1HCK and 3LN1 was achieved by
experimental docking of ATP and Celecoxib to their binding sites respectively. They exhibited
docking patterns equivalent to the original electronic crystal structures of 1HCK and 3LN1.

1

Two derivatives developed in Faculty of Pharmacy - Beirut Arab University, as apart of pharmacist Zahra
Kassem PhD thesis.
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2.3. Pharmacokinetic in-Silico Studies
The 2D chemical structures were drawn on Swiss ADME submission page (Swiss Institute
of Bioinformatics, 2021). Computation of physicochemical properties and drug-likeness was
appraised and displayed as Bioavailability Radar. Binding to permeability glycoprotein (P-gp)
and inhibiting cytochrome P450 (CYP) isoforms were estimated by applying support vector
machine algorithm (SVM). Gastrointestinal (GI) absorption and blood brain barrier (BBB)
penetration was predicted by boiled-egg model. The bioavailability is calculated according to
Abbott score (Martin, 2005).

3. DISCUSSION AND RESULTS
3.1. Prediction of Pharmacodynamic Properties
In this study, aiming at discovering new derivatives having twin effect as antiinflammatory and CDK2 suppressor effectiveness, the hopeful anti COX2 activity of DZBAU2021-6 and DZ-BAU2021-14 was in-silico studied. The current work examines the
anticipated mode of receptor interaction of the novel CDK2 inhibitors, DZ-BAU2021-6 and DZBAU2021-14, on both CDK2 and COX2 receptor active sites and explores their hypothetical
binding affinities. In this respect DZ-BAU2021-6 and DZ-BAU2021-14 were docked to the
active site of 1HCK and 3ln1.

3.1.1. Binding mode of study compounds at cdk2 active site
To gain a perception of the binding mode of ATP with CDK2 and exploring the
protein-ligand pocket environment, their co-crystallized structure, 1HCK, was observed.
Analyzing the ATP pocket of 1HCK, as seen in PDB, it showed hydrogen bonds at the
level of Asn132, Asp145, Gln131, Glu81, Gly13, Leu83, Lys33, Lys129 and Thr14.
Purine nucleus was hosted by the hydrophobic parts of Ile10, Leu83, Leu134 and Val18
(Fig. 1).

Fig.1: 2D view of ATP interaction with CDK2 (pdb entry: 1HCK) (Protein Data Bank in
Europe; Schulze-Gahmen et al., 1996)

Molecular docking of pyrazolopyridine derivatives, and Roscovitine was carried
out against the treated 1HCK active binding site. ATP was redocked for validation, where
it demonstrated similar ligand-receptor adaptive fitting involving same amino acid
Published by Digital Commons @ BAU, 2021
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residue interactions. The estimated docking energies and 3D interaction models are
illustrated in Table 1 and Fig. 2-5.
Table 1: Ligand-protein docking energies in kcal/mol at the active site of 1HCK

Compound

Estimated
Free
Binding
Energy

DZ-7.35
BAU2021-6
DZBAU2021- -8.84
14
ATP

-6.21

Roscovitine -7.88
a

Estimated
Inhibition
Constant,
Ki,(µM)a

Final
Intermolecular
Energy

VdW
+Hbond
+desolv.
Energy

Electrostatic
Energy

Final
Total
Internal
Energy

Unboun
Torsional d
Free
System'
Energy
s
Energy

4.11

-8.35

-8.03

+0.01

-0.58

+0.30

-0.69

0.33

-10.12

-9.88

-0.24

-0.79

+1.19

-0.87

28.25

-10.70

-9.09

-1.61

-5.46

+4.18

-5.77

1.68

-9.58

-9.15

-0.43

-1.65

+2.68

-0.66

Estimated Inhibition Constant, Ki is characterized in Micro-molar concentration at Temperature = 298.15 K.

The estimated ligand-receptor free binding energy, upon redocking of ATP, was 6.21 kcal/mol (table 1). At its docking active site against prepared 1HCK, at the level of
ribose, ATP exhibited three H-bond donors with the side chain of Asp145 of 2.57, 2.95
and 3.20 Å, four H-bond acceptors of 2.74, 3.08, 3.17 and 3.59 Å bond distances with
amino group of Lys33. The phosphate residue dominated many hydrogen bonds; three
H-bond acceptors with Lys129 and three H-bonds involving the hydroxyl group of Thr14,
the carboxamide side chain of Asn132 and the back bone of Gly13 of 2.72, 3.00 and 3.14
Å respectively. Purine and ribose skeleton were hosted by the hydrophobic region formed
by Gln131, Gly13, Leu83, Leu134, Ile10, Lys129 and Val18 (Fig. 2).

Fig.2: 3D interaction model of ATP with CDK2 kinase (1HCK) upon redocking

DZ-BAU2021-6 revealed estimated free binding energy of -7.35 kcal/mol (table
1). Its 3D interaction binding model with CDK2 kinase (1HCK) illustrated two H-bond
acceptors at the level of pyrazolo N6 and pyridino N7 with amino group of Lys33 of 3.68
and 2.83 A˚ respectively. The carbon skeleton was seen lodged in the lipophilic pocket
formed by non-polar residues of Ileu10, Leu134 and Val18, with non-coplanar Van der
Walls forces of attraction involving benzene rings of Phe80 and Phe82 (Fig. 3).
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Fig.3: 3D interaction model of DZ-BAU2021-6 with CDK2 kinase (1HCK)

Compound DZ-BAU2021-14 showed estimated free binding energy of -8.84
kcal/mol (table 1). It displayed many H-bond interactions with various amino acid
residues at the active pocket of CDK2 kinase (1HCK); triazino N1 and N2 were
stabilized as two H-bond acceptors with Lys33 amino group of 2.98 and 2.75 Å
respectively. Two H-bond acceptors were depicted between the ligand ethanoate
carbonyl and NH groups of Lys129 and Thr14 with a bond distance 3.29 and 3.22 Å
respectively. In addition, the ethanoate oxygen was involved in H-bond acceptor of 3.18
Å length with NH group of Tyr15 while the methyl group elaborated a H-bond donor
3.14 Å with carbonyl side chain of Asp86. The exposed skeleton was accommodated in
a hydrophobic pocket formed by Gln131, Ile10, Leu134 and Val18 amino acid residues
(Fig. 4).

Fig.4: 3D interaction model of DZ-BAU2021-14 with CDK2 kinase (1HCK)

Docking of Roscovitine to CDK2 active pocket depicted a binding energy of 7.88 kcal/mol (table 1). Ligand-receptor interaction displayed H-bond acceptor of 3.21
Å between purine N3 and amino group of Lys33. In addition, butanol amino NH
established a H-bond donor of 3.11 Å with the carbonyl side chain of Asp86. The
hydroxyl group showed H-bond acceptor of 3.18 Å with amino group of Lys89 and Hbond donor of 2.67 Å with carbonyl side chain of Asp86. The carbon chains were
interacting hydrophobically with Gln131, Ile10 and Leu134 (Fig. 5).
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Fig.5: 3D interaction model of Roscovitine with CDK2 kinase (1HCK)

Both compounds DZ-BAU2021-6 and DZ-BAU2021-14 showed low levels of
estimated binding energies. DZ-BAU2021-14 illustrated the lowest binding energies
and the lowest estimated inhibition constant. It exhibited better binding criteria than
Roscovitine; -8.84, -10.12, and -9.88 Kcal/mol compared to -7.88, -9.58 and -9.15
Kcal/mol assigned to estimated free binding energy, final intermolecular energy and
total sum of Van der Walls + hydrogen bonding + desolvation energy, respectively. DZBAU2021-14 demonstrated one-fourth the estimated inhibition constant (Ki) of
Roscovitine (0.33 to 1.68 µM). The endogenous substrate ATP exhibited the best final
intermolecular energy (table 1). The final intermolecular energy value -10.12 Kcal/mol
assigned for DZ-BAU2021-14 compared to -1.70 Kcal/mol for ATP indicates the
stability of DZ-BAU2021-14 in its ligand-receptor complex pocket.

3.1.2. Binding Mode of Study Compounds at COX2 Active Site
The anti-inflammatory effect of DZ-BAU2021-6 and DZ-BAU2021-14 was tested
by inspecting their COX2 inhibitory activity in-silico; the anticipated binding interactions
and affinities to COX2 receptor were studied by docking them to the active site of COX2
using the prepared crystalline protein structure 3ln1. In parallel, the binding mode of
Celecoxib to COX2 receptor was explored to recognize the assembly of amino acidsligand setting.
The crystalline structure 3ln1 depicted the interaction of the embedded celecoxib
through H-bonds at the level of Arg499, Gln178, His75, Leu338, Phe504 and Val50 as
well as an assembly of pi-C, pi-H and hydrophobic interactions with Ala513, Gln178,
Gly513, Leu338, Phe504, Ser339, Tyr341, Val335 and Val509. Trifluoromethyl group
was logged in the lipophilic pocket created by Leu517, Tyr341 and Val335 (Fig. 6).

Fig.6: 2D view of Celecoxib interaction with COX2 (pdb entry: 3LN1) (Protein Data Bank in
Europe; Wang et al., 2010)
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Molecular docking of DZ-BAU2021-6 and DZ-BAU2021-14 was carried out
against the treated 3ln1 active binding site. Celecoxib was redocked for validation, it
proved analogous ligand-receptor interactions compared to the untreated 3ln1
crystallized ones, involving same amino acid residues. The estimated docking energies
and 3D interaction models are demonstrated in Table 2 and Fig. 7-9.
Table 2. Ligand-protein docking energies in kcal/mol at the active site of 3ln1

Compound

Estimated
Free
Binding
Energy

DZBAU2021- -7.50
6
DZBAU2021- -9.66
14
Celecoxib -9.47
a

Estimated
Inhibition
Constant,
Ki,(µM)a

Final
Intermolecular
Energy

VdW
+Hbond
+desolv.
Energy

Electrostatic
Energy

Final
Total
Internal
Energy

Torsional Unbound
Free
System's
Energy
Energy

3.20

-7.86

-7.85

-0.01

-0.62

+0.30

-0.69

0.08

-10.80

-10.63

-0.17

-0.93

+1.19

-0.87

0.11

-10.38

-10.36

-0.02

-0.13

+0.89

-0.14

Estimated Inhibition Constant, Ki is characterized in Micro-molar concentration at Temperature = 298.15 K.

DZ-BAU2021-6 showed low estimated free binding energy of -7.50 Kcal/mol. In
its 3D interaction model with COX2 crystallized structure (3ln1), it displayed a H-bond
donor of 3.62 Å length between methyl group and carbonyl side chain of Gln178 while
the exposed groups underwent hydrophobic contacts with Ala513, Leu338, Tyr341,
Val509 and Val335 (Fig. 7).

Fig.7: 3D interaction model of DZ-BAU2021-6 with COX-2 (3ln1)

DZ-BAU2021-14 demonstrated estimated free binding energy of -9.66 Kcal/mol.
Its binding interaction against COX2 crystallized structure (3ln1) displayed many Hbonds with different amino acid residues. Triazino methyl and ethanoate methylene
groups were stabilized by establishing H-bond donors with carbonyl side chain of Gln178
and carbonyl backbone of Leu338 with bond lengths 3.79 and 3.04 Å respectively. The
ethanoate carbonyl group exhibited a H-bond acceptor of 3.14 Å with the basic amino
acid Arg499. In addition, the triazino ring interacted with Val509 through two pi–H
bonds of 3.63 and 3.91 Å respectively. The exposed carbon skeleton was lodged in the
hydrophobic pocket formed by six amino acid residues Ala513, Leu338, Ser339, Tyr341,
Val335 and Val509 (Fig. 8).
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Fig.8: 3D interaction model of DZ-BAU2021-14 with COX-2 (3ln1)

Upon redocking of Celecoxib in its target binding site of COX2 crystallized
structure (3ln1), it showed estimated free binding energy of -9.47 Kcal/mol. Celecoxib
amino group was stabilized by establishing two interactions; H-bond donor with back
bone carbonyl of Val102 of 3.09 Å and H-bond acceptor with side chain NH of Arg106
of 2.69 Å. A pi-H bond of 3.96 Å length was depicted between the methyl substituted
phenyl and Val509. The exposed carbon backbone was hosted by the hydrophobic parts
of Ala513, Leu338, Leu517, Phe504, Ser339, Tyr341, Val335 and Val509 (Fig. 9).

Fig.9: 3D interaction model of Celecoxib with COX-2 (3ln1) upon redocking

The binding modes attributed to Celecoxib (Dhanjal et al., 2015), Valdecoxcib (Di
Fiore et al., 2006) and Rofecoxcib (Orlando & Malkowski, 2016) with COX2 receptor
were quite similar. They pointed a particular active pocket and same amino acid residues
that are shared with the study compounds DZ-BAU2021-6 and DZ-BAU2021-14. This
raised the presumption hits of their anti-inflammatory activity.
Estimated binding energies for DZ-BAU2021-6 and DZ-BAU2021-14 indicated
binding affinities to COX2 receptor (3ln1) (table 2). According to the obtained values
DZ-BAU2021-14 showed the lowest binding energies and estimated inhibition constant
(Ki). Compared to Celecoxib, DZ-BAU2021-14 showed -9.66, -10.80 and -10.63
Kcal/mol to -9.47, -10.38 and -10.36 Kcal/mol for Celecoxib specifying their estimated
free binding energy, final intermolecular energy and total sum of Van der Walls +
hydrogen bonding + desolvation energy, respectively. DZ-BAU2021-14 demonstrated
three-fourth the estimated inhibition constant (Ki) of Celecoxib (0.08 to 0.11µM). From
the previous data, DZ-BAU2021-14 revealed superior binding interactions with COX2
crystalline structure (3ln1) compared to Celecoxib. This can be proved considering not
only its lower values at the level of binding energies and estimated inhibition constant,
but also possessing higher number of hydrogen bonding and additional pi-H interactions
at the active pocket of COX2 involving more amino acid residues than Celecoxib does.

https://digitalcommons.bau.edu.lb/hwbjournal/vol4/iss1/4
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3.2. Prediction of Pharmacokinetic Properties
As the penetration of DZ-BAU2021-14 to colorectal cell lines HCT-116 and HT-29 was
proven by its antiproliferative CDK2 inhibitory activity as concluded from its biological in- vitro
results (Kassem et al., 2021), tracing its physicochemical and pharmacokinetic properties is
fundamental to develop an idea about its bioavailability and different tissue concentration. In
this respect Swiss ADME web tool (Daina et al., 2017; Swiss Institute of Bioinformatics, 2021)
was used to evaluate the pharmacokinetics and drug-likeness of DZ-BAU2021-6 and DZBAU2021-14.
From the first glance the Bioavailability Radar presentation of compound DZ-BAU20216 reflected high lipophilicity and low polarity levels with notably limited flexibility and high
unsaturation level (Fig.10). The estimated n-octanol/water partition coefficients expressed as
Log Po/w demonstrated a range of values between 2.94-3.87 with a consensus Log Po/w of 3.60
predicting high lipophilicity. Water solubility was read as poor to moderate. Compound DZBAU2021-6 exhibited a high estimated GI absorption, BBB penetration. It was detected as a
substrate for permeability glycoprotein (P-gp) and showed inhibitory potential to CYP1A2,
CYP2C19, CYP2C9 and CYP3A4 while it had no effect on CYP2D6. Swiss ADME described
compound DZ-BAU2021-6 as a drug-like having bioavailability score of 0.55. No violation was
depicted.
Compared to DZ-BAU2021-6, compound DZ-BAU2021-14 showed in its Bioavailability
Radar presentation slight lower lipophilicity and less polarity. Higher flexibility and saturation
levels were observed (Fig. 10). Compound DZ-BAU2021-14 exhibited lower order of
lipophilicity; its estimated n-octanol/water partition coefficients were ranging between 2.90-3.43
with a consensus Log Po/w value of 3.16, anticipating optimum lipophilic behavior with poor to
moderate water solubility scores. The predicted pharmacokinetic properties illustrated high GI
absorption, and no BBB penetration. It was not assigned as a P-gp substrate which boosts its
intracellular concentration and limits it efflux. Compound DZ-BAU2021-14 demonstrated
inhibitory activity for CYP1A2, CYP2C19 and CYP2C9 while it had no effect on CYP2D6 and
CYP3A4. It was defined as a drug-like exhibiting bioavailability score of 0.55 with no violation.

DZ-BAU2021-14

DZ-BAU2021-6

Fig.10: Bioavailability Radar describing lipophilicity, size, polarity, insolubility, unsaturation and
flexibility

The estimated high levels of lipophilicity and low levels of polarity and water solubility
in addition to GI absorption indicated potential oral bioavailability for both candidates DZBAU2021-6 and DZ-BAU2021-14 and postulated them for drug-likeness. Superior pattern was
observed for DZ-BAU2021-14; it was not determined P-gp substrate which would reflect its
intracellular concentration. In addition, it revealed lower potential for drug-drug interaction at
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the level of CYP inhibition in comparison to DZ-BAU2021-6. Moreover, having no BBB
penetration, it is hypothesized to grace no central side effect.

4. CONCLUSION
Understanding the complementary response associated to COX2 and CDK2 inhibition in
controlling cell proliferation and prognosis of colorectal cancer, the current work affords the
computational studies of DZ-BAU2021-6 and DZ-BAU2021-14 depicting the superior in-silico
activity of the CDK2 inhibitor DZ-BAU2021-14 against COX2 receptor model compared to
Celecoxib. DZ-BAU2021-14 exhibited high GI absorption along with absence of P-gp interference
and lower CYP interaction which promotes its nomination as an individual candidate assembling
CDK2-COX2 inhibitory effects against colorectal cancer cells with designated oral activity and low
drug-drug interaction possibilities. This might inaugurate the discovery of discrete CDK2-COX2
inhibitors and add exponential highlights towards a dual scope activity saving pharmacokinetic loads
of individual drug combination.
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